home / stock / dtil / dtil quote
Last: | $ |
---|---|
Change Percent: | 3.77% |
Open: | $8.00 |
Close: | $8.26 |
High: | $8.31 |
Low: | $7.88 |
Volume: | 671,398 |
Last Trade Date Time: | 02/12/2020 04:40:53 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$ | $8.00 | $8.26 | $8.31 | $7.88 | 671,398 | 02-12-2020 |
$ | $8.49 | $7.96 | $8.575 | $7.86 | 587,344 | 02-11-2020 |
$ | $8.29 | $8.49 | $8.57 | $8.19 | 503,929 | 02-10-2020 |
$ | $8.84 | $8.22 | $8.93 | $8.11 | 719,856 | 02-07-2020 |
$ | $8.42 | $8.69 | $8.94 | $8.37 | 624,995 | 02-06-2020 |
$ | $8.26 | $8.35 | $8.60 | $8.03 | 467,804 | 02-05-2020 |
$ | $8.31 | $8.19 | $8.69 | $8.02 | 538,057 | 02-04-2020 |
$ | $8.10 | $8.22 | $8.35 | $7.71 | 685,423 | 02-03-2020 |
$ | $8.26 | $8.09 | $8.39 | $7.81 | 648,990 | 01-31-2020 |
$ | $8.90 | $8.31 | $8.9717 | $8.19 | 727,156 | 01-30-2020 |
$ | $9.12 | $8.96 | $9.27 | $8.775 | 584,817 | 01-29-2020 |
$ | $9.65 | $9.12 | $9.80 | $8.77 | 771,986 | 01-28-2020 |
$ | $9.93 | $9.58 | $10.0182 | $9.42 | 994,052 | 01-27-2020 |
$ | $10.16 | $9.93 | $10.29 | $9.72 | 722,315 | 01-24-2020 |
$ | $10.26 | $10.10 | $10.70 | $9.86 | 765,471 | 01-23-2020 |
$ | $10.51 | $10.25 | $10.85 | $10.10 | 565,530 | 01-22-2020 |
$ | $10.82 | $10.63 | $11.19 | $10.50 | 578,812 | 01-21-2020 |
$ | $11.19 | $10.68 | $11.46 | $10.51 | 801,417 | 01-20-2020 |
$ | $11.19 | $10.68 | $11.46 | $10.51 | 800,591 | 01-17-2020 |
$ | $11.62 | $11.09 | $11.66 | $10.63 | 1,843,791 | 01-16-2020 |
News, Short Squeeze, Breakout and More Instantly...
Precision BioSciences Inc. Company Name:
DTIL Stock Symbol:
NYSE Market:
Precision BioSciences Inc. Website:
Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, today announced its addition to the Russel...
Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, is presenting data today at the United Mit...
Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, today announced the appointment of Mark Su...